arrow
S

Shahrokh F. Shariat

aou san giovanni battista-molinette
H指数:146
被引数:9.9万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer

对偶然性前列腺癌中新型风险分层模型与当前cT1a/b分期的比较

2026-09-290
PRE
An Assessment of PI-RADS v2.1: Inter-Reader Agreement, Diagnostic Accuracy, and the Added Value of PSA Density in Prostate Cancer Prediction

PI-RADS v2.1评估:阅片者间一致性、诊断准确性及前列腺特异性抗原密度在前列腺癌预测中的附加价值

2026-09-210
OA
Role of Second-Look Ureterorenoscopy After Endoscopic Treatment of Upper Tract Urothelial Carcinoma

上尿路尿路上皮癌内镜治疗后二次输尿管肾镜检查的作用

Cancers
IF4.4
2026-09-080
OA
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis

预测高危非肌层浸润性膀胱癌患者中BCG无应答疾病的发展:一项国际多中心分析

2026-09-010
OAAI
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin

非肌肉浸润性膀胱癌患者接受卡介苗治疗后年龄的影响

2026-05-010
PRE
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

良性前列腺增生手术后偶发前列腺癌的风险因素:一项系统评价和荟萃分析

2026-03-230
PRE
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels

膀胱癌治疗中使用留置性膀胱内药物释放系统的不良反应管理及操作最佳实践:专家小组建议

2026-01-010
PRE
Oncological outcomes of deferred systemic therapy for patients with metastatic renal cell carcinoma: A systematic review and quantitative analysis

延期全身性治疗对转移性肾细胞癌患者肿瘤学结局的影响:一项系统评价和定量分析

2026-01-010
PRE
Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette–Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https://doi.org/10.1016/j.annonc.2025.09.017

Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): 一项第3期、随机、开放标签、国际性临床试验,比较静脉注射阿替利珠单抗联合膀胱内注射卡介苗(BCG)与单用BCG治疗BCG初治高危非肌层浸润性膀胱癌(NMIBC)。《肿瘤学年鉴》。待发表。https://doi.org/10.1016/j.annonc.2025.09.017

2025-12-150
OAAI
Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low Uptake

前列腺癌胚系基因检测的地理变异性:一项基于全国性医疗保险索赔数据的研究,显示其采用率较低

2025-12-010
PRE
Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomy

组织学分级是否是浸润性尿路上皮膀胱癌的有用参数?来自一项关于不同分级系统对根治性膀胱切除术术后无病生存期影响的多中心研究的结果

2025-11-200
OAAI
Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy

炎症性肠病与根治性前列腺切除术后的院内不良结局比较

2025-11-010
PRE
Sarcomatoid dedifferentiation as a predictor of overall mortality in surgically treated metastatic renal cell carcinoma
2025-11-010
PRE
Corrigendum to “Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials”. [Clin. Translat. Radiat. Oncol. 47 (2024) 100801]

勘误:“盆腔骨髓保护放射治疗宫颈癌的临床结局:一项随机对照试验的系统评价和荟萃分析”。[Clin. Translat. Radiat. Oncol. 47 (2024) 100801]

2025-10-180
OAAI
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy

截瘫患者接受根治性前列腺切除术的院内不良结局

2025-10-100
OAAI
Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

PSMA靶向放射性配体疗法在转移性去势抵抗性前列腺癌中的预后因素:一项系统综述和荟萃分析

2025-10-080
OA